| ||
Vivus Shares Feel The Pain: Blockbuster Diet Drug Likely Won't Be Sold In Europe Forbes Vivus stock slumped more than 10% this morning after the company said its weight-loss drug will likely be denied approval in Europe. The European Medicines Agency will make a formal decision on the drug, Qsiva, at a meeting next month. But initial ... See all stories on this topic » | ||
| ||
| ||
Diet high in total antioxidants associated with lower risk of myocardial ... Medical Xpress "Our study was the first to look at the effect of all dietary antioxidants in relation to myocardial infarction," says lead investigator Alicja Wolk, DrMedSci, Division of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska ... See all stories on this topic » |
Tip: Use quotes ("like this") around a set of words in your query to match them exactly. Learn more.
Delete this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment